BSE Live
Oct 21, 15:06Prev. Close
1282.40
Open Price
1285.05
Bid Price (Qty.)
1289.55 (8)
Offer Price (Qty.)
1289.55 (11)
NSE Live
Oct 21, 15:10Prev. Close
1282.00
Open Price
1288.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1288.70 (407)
Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 7,235.90 | 5,791.30 | 3,866.00 | 2,223.80 | 3,056.20 | |
Net CashFlow From Operating Activities | 4,225.00 | 3,449.70 | 5,052.90 | 1,338.70 | 3,514.20 | |
Net Cash Used In Investing Activities | -5,697.60 | -3,430.30 | -3,447.60 | -2,038.00 | -1,458.00 | |
Net Cash Used From Financing Activities | 1,590.70 | 68.10 | -2,696.90 | 505.50 | -794.30 | |
Foreign Exchange Gains / Losses | 0.20 | 1.60 | 44.50 | 47.90 | 4.40 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Inc/Dec In Cash And Cash Equivalents | 118.30 | 89.10 | -1,047.10 | -145.90 | 1,266.30 | |
Cash And Cash Equivalents Begin of Year | 201.40 | 112.30 | 1,159.40 | 1,305.40 | 39.10 | |
Cash And Cash Equivalents End Of Year | 319.70 | 201.40 | 112.30 | 1,159.50 | 1,305.40 |
17.09.2025
15.09.2025
11.09.2025
28.08.2025
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
23.07.2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs 1,418 crore, revenue up 11%
12.05.2025
Dr Reddys Labs Standalone March 2025 Net Sales at Rs 5,562.90 crore, up 8.97% Y-o-Y
12.05.2025
Dr Reddys Labs Consolidated March 2025 Net Sales at Rs 8,528.40 crore, up 19.89% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz